If you have lost weight on Mounjaro or Zepbound, sooner or later you will probably ask: what happens if I stop? It’s a fair question. The medication is expensive, insurance coverage changes, and you want to know whether your results will last.
The clearest answer comes from SURMOUNT-4, the large clinical trial built to test what happens when people stop tirzepatide. Most people who stopped regained a large share of their weight, but not all of it. People who stayed on treatment kept losing weight.
What Makes Tirzepatide Different
Tirzepatide is a dual-action medication. It activates two gut hormone receptors, GLP-1 and GIP. Semaglutide (Ozempic and Wegovy) activates only GLP-1. Together, these two signals reduce appetite, slow digestion and improve blood sugar control.
That dual action helps explain why tirzepatide often leads to more weight loss. In the SURMOUNT-1 trial, people on the 15 mg dose lost about 21% of their body weight over 72 weeks.
A stronger effect while you take it does not protect you from regain after you stop, though. Once the medication leaves your system, the appetite signals it was controlling go back to how they were.
The SURMOUNT-4 Trial: What Happened When People Stopped
SURMOUNT-4 enrolled adults with obesity or overweight who did not have diabetes. For the first 36 weeks, everyone took tirzepatide at the highest dose they could tolerate, either 10 mg or 15 mg. Then 670 participants were randomly assigned either to keep taking tirzepatide or to switch to a placebo for another 52 weeks. Neither the participants nor their doctors knew who got which.
After 36 weeks on tirzepatide, participants had lost an average of 20.9% of their body weight. Over the next 52 weeks, those who stayed on tirzepatide lost another 5.5%, while those switched to placebo regained 14%. That is a gap of 19.4 percentage points between the two groups.
The Numbers That Matter Most
- People who stayed on tirzepatide lost 25.3% of their starting weight by the end of the trial.
- People who stopped still finished 9.9% below their starting weight.
- 89.5% of people who stayed on tirzepatide kept at least 80% of their weight loss. Only 16.6% of people who stopped managed the same.
In short, stopping did not undo everything. People who switched to placebo still weighed about 10% less than when they started. But most of them lost more than half of their progress within a year. The researchers also saw improvements in blood pressure, cholesterol and blood sugar partly reverse after people stopped.
What SURMOUNT-4 Did Not Test
Everyone in the placebo group stopped abruptly, with no taper. Doses were not adjusted during the second phase of the trial. So SURMOUNT-4 shows what happens after a sudden stop. It does not show what happens if you lower your dose gradually with a provider’s help.
The trial also left out people with type 2 diabetes. If you take Mounjaro for diabetes, your provider will weigh other factors before changing your dose.
The Dosing Schedule
Tirzepatide is dosed the same way for both Mounjaro and Zepbound:

- Weeks 1 to 4: 2.5 mg once weekly, a tolerability dose not expected to produce significant weight loss
- Every 4 weeks after: the dose increases, 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg
- Maintenance: the dose that achieves your goals with tolerable side effects. FDA-approved maintenance doses are 5 mg, 10 mg, or 15 mg weekly
Can You Stay on a Lower Dose of Tirzepatide?
Often, yes. Once they reach their goal, some patients keep their results on 5 mg or 10 mg a week instead of 15 mg. Lower the dose slowly, and only with your provider tracking your weight. We cover tapering options in detail in our tirzepatide maintenance dose guide.
Modeling studies suggest that switching from weekly to every-other-week dosing can cut costs by 50 percent while retaining 70 to 95 percent of weight loss, depending on the dose. This is an emerging strategy that may become more common as long-term data accumulate.
Tirzepatide vs. Semaglutide: Weight Regain at a Glance
| Trial | Medication | Time on medication before the switch | Weight lost before the switch | One year after switching to placebo | Those who stayed on the medication |
|---|---|---|---|---|---|
| SURMOUNT-4 | Tirzepatide (10 or 15 mg) | 36 weeks | 20.9% | Regained 14%, still 9.9% below starting weight | Lost another 5.5% (25.3% total) |
| STEP 4 | Semaglutide (2.4 mg) | 20 weeks | 10.6% | Regained 6.9% over 48 weeks | Lost another 7.9% (17.4% total) |
| STEP 1 extension | Semaglutide (2.4 mg) | 68 weeks | 17.3% | Regained about two-thirds of the weight lost, ending 5.6% below starting weight | Not tested (everyone stopped) |
These trials used different designs and timelines, so they are not a direct head-to-head comparison. They all show the same pattern, though: weight comes back after the medication stops and stays off while it continues.
For the full semaglutide data, see our guide on gaining weight after stopping Ozempic.
Frequently Asked Questions
Your appetite usually returns over the following weeks, and weight starts to come back. In SURMOUNT-4, people who stopped regained 14% of their body weight within a year.
It varies from person to person. On average, people in SURMOUNT-4 regained more than half of what they had lost. They still ended about 10% below their starting weight.
Most people don’t, based on the trial data. A small group keeps most of their results. In SURMOUNT-4, 16.6% of people who stopped kept at least 80% of their weight loss.
The pattern is similar for both. Tirzepatide trials show larger numbers in both directions because people lost more weight to begin with. No trial has compared regain on the two drugs head to head.
Yes, and a supervised step down is usually better than stopping suddenly. SURMOUNT-4 only tested an abrupt stop. Read more about safely lowering your dose in our tirzepatide maintenance dose guide.
Partly. In SURMOUNT-4, improvements in blood pressure, cholesterol and blood sugar moved back toward where they started after people stopped tirzepatide.
The Same Rules Apply
Whatever medication you take, three habits do the most to protect your results:
- Plan any change with your provider. Lower your dose gradually instead of stopping suddenly.
- Strength train regularly. Lifting or resistance work helps you keep muscle while you lose fat.
- Eat enough protein. Aim for about 1.2 to 1.5 g per kg of body weight each day. Our nutrition counseling team can help you plan meals around it.
Thinking About Stopping? Talk to Us First
Everest eClinic is a telehealth practice for patients in Connecticut and Texas. If you’re thinking about stopping or lowering your tirzepatide dose, book a visit with Geeta Sharma, DNP, NP-C. Together you can build a plan that fits your goals and your budget.
Explore our weight loss treatment or book a 15 to 30 minute consultation.
Sincerely,
Geeta Sharma,
DNP Endocrinology Nurse Practitioner
Everest Diabetes & Weight Loss
Connecticut: (203) 689-0558 Office Phone or Text
Texas: Call: 512-541-2126

This article is for informational purposes and does not replace individualized medical advice. Talk to your provider before starting or stopping any medication.




